Scynexis’ Phase III Success Brings New Antifungal Class Closer To Approval

 
• By Joseph Haas

Biotech plans to file its first-in-class triterpenoid agent for approval in 2020 following a second Phase III study in acute vulvovaginal candidiasis. Beyond that, it hopes for a supplemental approval in recurrent VVC.

SC1911_Candida-auris-fungi_1164101620_1200.jpg
Ibrexafungerp is being developed for acute and recurrent VVC

More from Strategy

More from Business